Journal article
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
Abstract
PURPOSE: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl-modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA, has a prolonged tissue half life, enhances drug efficacy in xenograft models, and reduces clusterin expression in humans with a biologically effective dose of 640 mg. The objective of this …
Authors
N. K; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W
Journal
Clinical Cancer Research, Vol. 14, No. 3, pp. 833–839
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 1, 2008
DOI
10.1158/1078-0432.ccr-07-1310
ISSN
1078-0432